Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?

Citation:

Dan Gibson. 2021. “Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?” Journal of inorganic biochemistry, 217, Pp. 111353.

Abstract:

Pt(IV) complexes are designed as prodrugs that are intended to overcome resistance. Pt(IV) prodrugs are activated inside cancer cells releasing cytotoxic Pt(II) drugs as well as two axial ligands that can be used to confer favorable pharmacological properties to the prodrug. The ligands can be innocent spectators, cancer targeting agents or bioactive moieties. The choice of axial ligands determines the chemical and pharmacological properties of the prodrugs. Over the years, several approaches were employed in attempts to increase the selectivity of the prodrugs to cancer cells and to utilize multi-action prodrugs to overcome resistance. In this review, we critically examine several of these approaches in order to evaluate the validity of some of the working hypotheses that are driving the current research.